Table II.
Definitions of the Metabolic Syndrome
| Metabolic Factor | NCEP ATP III AHA/NHLBI 12 Any 3 of 5 Factors | WHO 13 Insulin Resistance (Type 2 DM, IFG, IGT) + Any 2 | AACE 14 Diagnosis Depends on Clinical Judgment Based on Risk Factors |
|---|---|---|---|
| Waist circumference, in | M, ≥40; F, ≥35 | ||
| BMI, kg/m2, and/or | >30 and/or | ≥25 | |
| waist/hip ratio | M, >0.9; F, >0.85 | ||
| Triglycerides, mg/dL | ≥150 | ≥150 | ≥150 |
| HDL cholesterol, mg/dL | M, <40; F, <50 | M, <35; F, <40 | M, <40; F, <50 |
| Blood pressure, mm Hg | ≥130/85 | ≥140/90* | ≥130/85 |
| Glucose, mg/dL | ≥100 | 110–126; | |
| >140 2 h after glucose challenge | |||
| Urinary albumin, mg/min | >20 | ||
| Albumin/creatinine ratio, mg/g | >30 | ||
| NCEP ATP III indicates National Cholesterol Education Program Adult Treatment Panel III; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; WHO, World Health Organization; DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; AACE, American Association of Clinical Endocrinologists; BMI, body mass index; HDL, high‐density lipoprotein; M, male; and F, female. *Or on drug therapy. | |||